Solasia Pharma KK (JP:4597)
:4597
Want to see JP:4597 full AI Analyst Report?
4597 Stock Chart & Stats
¥27.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥27.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥21.00 - ¥48.00
Previous CloseN/A
Volume8.51M
Average Volume (3M)41.98M
Market Cap
¥6.01B
Enterprise Value¥5.62B
Total Cash (Recent Filing)¥1.57B
Total Debt (Recent Filing)¥86.00M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding273,414,370
10 Day Avg. Volume52,616,870
30 Day Avg. Volume41,982,023
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Bulls Say, Bears Say
Bulls Say
Specialty Oncology FocusA focused oncology and supportive-care mandate positions the company in high-barrier, clinically driven markets with predictable long-term demand. Concentration on unmet needs helps sustain pricing power, partner interest, and durable product pipelines that can generate multi-year revenue streams once commercialized.
Partnering-driven Revenue ModelA business model mixing direct commercialization with licensing and milestone-based partnerships diversifies cashflow sources and limits sole dependence on product sales. Structural partner payments (upfronts, milestones, royalties) can provide non-linear funding cadence and reduce capital needs for R&D and market expansion.
Conservative Balance Sheet / Low LeverageVery low financial leverage preserves flexibility to fund development and absorb operating shortfalls without large interest burdens. A conservative balance sheet supports ability to negotiate partnerships or raise equity on better terms and reduces bankruptcy risk during extended commercialization timelines.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow indicates the company must continually access external capital or partner funding to sustain operations. Over months this pressurizes runway, can dilute shareholders if equity is issued, and limits reinvestment into commercialization or pipeline development absent larger partner receipts.
Deep Negative ProfitabilityA deeply negative net margin shows costs far exceed current revenue scale, implying structural unprofitability until revenues rise or costs are restructured. Persistent losses depress returns, restrict ability to self-fund expansion, and increase reliance on partners or financings over the next several quarters.
Modest And Declining Revenue; Weak Operating LeverageDeclining top-line and lack of operating leverage suggest the company has not yet scaled commercial operations. Without durable revenue growth, fixed costs remain burdensome and margin improvement is unlikely, stretching timelines to break-even and making long-term funding needs more acute.
Solasia Pharma KK News
4597 FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was ¥21.00 and its highest was ¥48.00 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is ¥6.01B.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is Aug 19, 2026 which is in 74 days.
How were Solasia Pharma KK’s earnings last quarter?
Solasia Pharma KK released its earnings results on May 15, 2026. The company reported -¥1.14 earnings per share for the quarter, missing the consensus estimate of N/A by -¥1.14.
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 273,414,370 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Solasia Pharma KK reported an EPS of -¥1.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in JP:4597
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―
Options Prices
Currently, No data available
---